Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGEM
HOLDCullinan Therapeutics, Inc. · Healthcare · United States · $1.1B · Avg Vol: $18M/d
COMPANY DESCRIPTION
Cullinan Therapeutics, Inc. is a clinical-stage oncology company developing a diversified pipeline of targeted therapies for cancer, utilizing various modalities like antibody-drug conjugates (ADCs) and bispecific antibodies. It focuses on innovative approaches to cancer treatment, leveraging a broad portfolio of early-stage assets and a management team with expertise in oncology drug development to address unmet medical needs. Cullinan is a clinical-stage biopharmaceutical company dedicated to oncology, with a pipeline designed for diverse cancer targets.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 17.8M | 40.4M | — |
| EPS | -1.52 | 2.46 | -3.21 | -2.78 | -3.36 | — | -3.33 | -3.00 | -2.53 | — |
| Shares | — | 45.8M | 42.9M | 58.5M | 60.2M | +31.5% | 61.5M | — | — | — |
| Debt | — | 5.2M | 3.6M | 2.2M | 2.7M | -19.7% | 2.4M | — | — | — |
| Equity | — | 535.0M | 453.7M | 590.3M | 408.7M | -8.6% | — | — | — | — |
| Op CF | — | -126.7M | -134.3M | -145.3M | -175.8M | — | -178.6M | — | — | — |
| Inv CF | — | 249.0M | 35.8M | -136.3M | 180.0M | — | — | — | — | — |
| Fin CF | — | -25.9M | 40.8M | 266.2M | 1.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGEM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc.(you) | $1.1B | 37 | HOLD |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 37 | HOLD |
| NVAX | Novavax, Inc. | $1.2B | 37 | HOLD |
| ANRO | Alto Neuroscience, Inc. | $940M | 35 | SELL |
| MGTX | MeiraGTx Holdings plc | $1.1B | 33 | SELL |
| LBRX | LB Pharmaceuticals Inc | $1.0B | 42 | HOLD |
| FBRX | Forte Biosciences, Inc. | $1.1B | 32 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| 0KCS.L | OPKO Health, Inc. | $734M | 37 | HOLD |
| SEPN | Septerna, Inc. | $1.5B | 36 | HOLD |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%